ConcertAI, a leader in oncology predictive, generative, and agentic AI SaaS and Real-World Data (RWD) solutions for healthcare and life sciences, has officially published its FY2024 business results, key partnerships, and future roadmap at the 43rd annual J.P. Morgan Healthcare Conference.
According to certain reports, the year 2024 saw 72% of ConcertAI’s total revenues becoming annually recurring (ARR), which is also the highest ever achieved by the company.
Next up, the company’s Commercial Solutions SaaS managed service business would go on to realize significant growth throughout, and as a result of that, it now has more than 80 therapeutics under agreement. Beyond that, ConcertAI would also leverage its CancerLinQ® network to enable well over 5.5 million multi-modal oncology RWD records.
Alongside that, the company went on to serve more than 40 biopharma users while simultaneously completing over 1,000 projects. It facilitated a larger chunk of those projects using Patient360™ DaaS solution.
In case that wasn’t enough, ConcertAI is now also planning to launch new Data-as-a-Service (DaaS) and AI Software-as-a-Service (SaaS) solutions built from the CARAai™ Platform in 2025.
Turning our attention towards some of the company’s key collaborations that materialized during 2025, they begin from its strategic multi-year, translational partnerships with multiple biopharma companies, including Dewpoint Therapeutics and AbbVie. The idea behind these partnerships was to support high-priority early clinical development programs with leading clinico-molecular RWD & AI SaaS Solutions.
Next up, ConcertAI formalized leading in-class clinico-molecular partnerships with Caris Life Sciences, NeoGenomics, and Guardant to create a differentiated molecular oncology platform for precision oncology research. The company also worked alongside NewGenomics to co-develop an AI SaaS solution. This particular solution has been meticulously designed to optimize clinical trials in hematology, the industry’s highest growth area for R&D.
The company also collaborated with NVIDIA on translational and clinical Development solutions, utilizing oncology-tuned NVIDIA NIM microservices. The list of microservices deployed here includes Llama 3 NIM microservice, Vision LM, and NVIDIA CUDA-X microservices, each one capable of developing a new model for entirely AI-based data curation, LLM model development, and high-performance enterprise-grade service.
For 2025, the companies will leverage one newly-introduced ConcertAI TeraRecon AI SaaS solutions to expand medical imaging.
“With the FDA guidance released a week ago, entitled ‘Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products,’ the need for representative data and clearly framed ‘Context of Use’ criteria will place a higher burden of performance on AI model and application developers,” said Jeff Elton, CEO of ConcertAI. He went on to add that, “over the last year, ConcertAI has been making significant investments around the CancerLinQ network to address these new AI for Healthcare and Life Sciences requirements – making it one of the few RWD sources in oncology and hematology.”
These developments deliver a rather interesting follow-up to ConcertAI’s acquisition of American Society of Clinical Oncology’s CancerLinQ® entity, which is understood to be one of the largest intelligent oncology research and quality networks in the world.
For better understanding, the stated network is also one of the few large-scale and independent data sources. We get to say so because most other sources are aligned to an EMR, diagnostic lab, or single healthcare provider.
Not just that, the whole thing also comes shortly after the release of a McKinsey report, where it was revealed that the use of artificial intelligence solutions by life science companies and healthcare providers is set to grow at a very high rate, approaching $26B or more for Life Science applications alone.
Founded in 2018, ConcertAI’s rise up the ranks stems from its leading multi-modal research-grade Data-as-a-Service (DaaS) and AI Software-as-a-Service (SaaS) capabilities that provide solutions to 50 life science companies, as well as 2,000 healthcare providers and research sites globally.
“Introducing generative AI tools to clinical trials is an important step forward in advancing drug development,” said Stacie Calad-Thomson, Ph.D., Business Development Lead for Healthcare and Life Sciences, North America, at NVIDIA. “Combining NVIDIA NIMs with ConcertAI’s platform improves how clinical trials are designed and executed, helping lead to better patient outcomes.”
